ENTECAVIR

Post-LOE

entecavir

BrightGene
ANDAORALTABLET
Approved
Sep 2019
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

[see Microbiology (12.4)].

Indications (6)

chronic hepatitis B virus infection in adultschildren at least 2 years of age with evidence of active viral replicationeither evidence of persistent elevations in serum aminotransferases (ALTAST)histologically active diseasehepatitis B

Clinical Trials (5)

NCT05494528N/AUnknown

Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy

Started May 2021
NCT04180150Phase 2Unknown

A Study of TQ-A3334 Combined With Entecavir in the Treatment of Chronic Hepatitis B

Started Nov 2019
NCT04157257Phase 2Unknown

An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy

Started Jul 2019
NCT03847246N/ACompleted

Bioequivalence Study of Entecavir Tablets and Baraclude® Under Fasting Condition in Chinese Healthy Volunteers

Started Dec 2018
NCT03577171Phase 2Completed

A Study Evaluating ABI-H0731+ Entecavir vs Entecavir Alone for the Treatment of Viremic HBeAg-positive Participants With Chronic Hepatitis B Virus Infection (cHBV)

Started Jun 2018
Company
B
BrightGene
China - Suzhou
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers